Ryan Sugarman, MD | Authors

Articles

Takeaways From CheckMate-649 in Gastric/GEJ/Esophageal Cancers

July 14, 2022

Ryan Sugarman, MD, discusses the key takeaways from the CheckMate-649 trial of patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma receiving nivolumab combined with chemotherapy compared with chemotherapy alone in the first-line.